• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

FDA Panel Votes to Expand Use of Pneumococcal Vaccine to Adults

Article

An FDA advisory committee has voted 14-1 in favor of expanding the indication for the pneumococcal 13-valent conjugate vaccine (Prevnar 13) to include use in adults 50 and older.

Currently the vaccine is approved only for use in children.

The FDA's Vaccines and Related Biologics Advisory Committee voted for accelerated approval, reserved for biologics or drugs that are intended to treat serious or life-threatening illnesses and that provide a meaningful benefit over existing treatments.

Read the full story at: http://www.medpagetoday.com/InfectiousDisease/Vaccines/29755

Source: MedPage Today

Related Videos
1 expert is featured in this series.
5 experts are featured in this series.
Dawn Klemow, MD, assistant clinical professor, The University of Texas Southwestern Medical Center
1 expert is featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.